Comparison of impurity profiles – and problematic HCPs – in mAbs

Dec 2020 by Rikke Lund

mab study webinar

How many protein impurities are present in antibody pharmaceuticals - and should we be concerned?

In this webinar, Rikke Lund - Head of HCP Characterization at Alpahlyse - shares her results from studying monoclonal antibodies (mAbs):
During the study, Rikke’s team analyzed 58 purified monoclonal antibodies, including 16 commercial mAbs and biosimilars - for their level of Host Cell Protein.

Surprisingly, the team found problematic HCPs in numerous mAb products. In addition, there were substantial differences between the HCP profiles of biosimilars and the originator.

Talk to us

Whatever protein-related challenge or question you may have, we would love to help. Our experts can help you decide on the best analytical approach for your project by email or online meeting - providing advice without obligation.

I would like an
This field is for validation purposes and should be left unchanged.